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Prenatal Diagnosis of Harlequin Ichthyosis
In 2005, ABCA12 was identified as 
the underlying gene causing harle-
quin ichthyosis (HI), and additional 
HI patients harboring ABCA12 
mutations have since been reported. 
Akiyama and colleagues report a 
successful prenatal diagnosis of HI 
using fetal genomic DNA obtained 
from amniotic fluid at an estimated 
gestational age of 17 weeks. Earlier 
prenatal diagnoses will be possible 
in the future through the use of com-
pletely noninvasive analysis of DNA 
from fetal cells in the maternal cir-
culation as well as preimplantation 
genetic diagnosis. See page 568 
Skin Barrier Recovery Is Temperature-Dependent
When Denda and co-workers varied the 
temperature from 36 °C to 40 °C in hair-
less mouse skin and human skin after tape 
stripping, epidermal permeability barrier 
recovery was accelerated as compared 
with the area at 34 °C. At 34 °C or 42 °C, 
barrier recovery was delayed as compared 
with the un-occluded area. Barrier recov-
ery was also accelerated or delayed with 
the topical application of various known 
activators or antagonists of transient recep-
tor potential temperature-sensor receptors, 
suggesting it may be possible to treat der-
matoses such as atopic dermatitis, psoria-
sis, and contact dermatitis by adjusting skin surface temperature. See page 654 
kit Mutation and Piebald Melanocyte Survival
To find out whether the kit mutation 
type affects the in vitro survival/pro-
liferation of human melanocytes 
in piebaldism, Bondanza and col-
leagues transplanted autologous cul-
tured epidermis to seven patients. An 
average repigmentation rate of 90.7% 
was documented, and six novel muta-
tions and one previously reported 
mutation were identified. Although the mutation type did not impair autotrans-
plantation repigmentation, it influenced the survival/proliferation of cocultured 
melanocytes and keratinocytes. The authors suggest that, before surgical operations on 
piebald patients are planned, mutations of cultured epidermis should be investigated. 
See page 676 
CRH: Inflammatory 
Mediator
Zbytek and Slominski 
studied the links among 
corticotropin-releasing 
hormone (CRH), bacteria, 
and inflammatory cytokines 
in human keratinocytes. 
Lipopolysaccharide (a toll-like 
receptor-4 agonist) but not 
PAM3CSK4 (a toll-like receptor-
2 agonist) stimulated expression 
of CRH mRNA. CRH stimulated 
expression of IL-1β, IL-6, and 
tumor necrosis factor-α mRNAs 
but not the expression of 
IL-10 mRNA. CRH may serve 
as a local autocrine mediator 
that amplifies inflammatory 
responses to bacterial antigens. 
It may be a target for treating 
psoriasis, alopecia areata, or 
acne. See page 730 
COX-2 Inhibition Ups 
Antitumor Responses
Inoue and Aramaki applied 
the model tumor antigen 
ovalbumin (OVA) to tape-
stripped skin in mice to 
test whether a COX-2 
inhibitor enhances the 
antitumor immune response 
induced by cytosine-
phosphate-guanosine-
oligodeoxynucleotide (CpG-
ODN). The COX-2 inhibitor 
remarkably enhanced the 
Th1-type immune response 
and generation of cytotoxic T 
lymphocytes. A transcutaneous 
vaccination with the inhibitor, 
CpG-ODN, and OVA was 
effective in inducing antigen-
specific antitumor immunity in 
vivo. Use of a COX-2 inhibitor, 
CpG-ODN, and tumor antigen 
appears to be a simple, cost-
effective strategy for tumor 
vaccination. See page 614 
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